Streetbeat News

Analyst Ratings

RGA

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on Reinsurance Gr (NYSE:RGA) and raises the price target from $168 to $169.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 12:02 pm

MA

MMM

MODV

ONON

PLUG

PYPL

SQ

V

Jim Cramer, on CNBC's 'Mad Money Lightning Round', expressed his preference for the stocks of Mastercard and Visa over PayPal and Block. He was uncertain about ModivCare and advised against investing in Plug Power due to poor numbers. He also mentioned issues with 3M Company related to the combat arms trial. Cramer expressed optimism for On Holding AG's upcoming earnings report, despite the stock's previous fall after good numbers.

Portfolio Pulse from Lisa Levin

August 15, 2023 | 12:01 pm

MNDY

Analysts have provided ratings for Monday.Com (NASDAQ:MNDY) within the last quarter, with 2 being bullish, 6 somewhat bullish, and 1 indifferent. The average price target is $204.44, implying an upside from the current price of $169.11. This average price target has increased by 16.63% over the past month.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 12:01 pm

GMAB

Analysts have provided mixed ratings for Genmab (NASDAQ:GMAB) in the last quarter, with 9 bullish and 8 somewhat bearish ratings. The average 12-month price target for Genmab over the past 3 months is $42.71, which has increased by 22.03% over the past month.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 12:01 pm

AFL

Wells Fargo analyst Elyse Greenspan maintains an Equal-Weight rating on Aflac (NYSE:AFL) and raises the price target from $71 to $78.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 12:01 pm

ROIV

In the last quarter, Roivant Sciences (NASDAQ:ROIV) received 5 bullish, 2 somewhat bullish, and 1 indifferent rating from analysts. The company's average price target has increased by 11.29% from the previous average of $15.33 to $17.06. The high and low price targets are $23.00 and $10.50 respectively.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 12:00 pm

TSHA

Analysts have provided bullish ratings for Taysha Gene Therapies (NASDAQ:TSHA) in the last quarter, with 5 bullish and 1 somewhat bullish ratings. The average price target has increased by 70.75% from the previous average of $4.00 to $6.83, implying an upside from the current price of $2.13.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 12:00 pm

PHVS

Over the past 3 months, 8 analysts have published their opinion on Pharvaris (NASDAQ:PHVS) stock. The company has an average price target of $13.0 with a high of $34.00 and a low of $10.00. The average price target has increased by 30.0% over the past month. Most analysts are indifferent about the stock.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 12:00 pm

BTAI

Truist Securities analyst Robyn Karnauskas maintains a 'Buy' rating on BioXcel Therapeutics (NASDAQ:BTAI), but has lowered the price target from $71 to $31.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 15, 2023 | 12:00 pm

HALO

In the last quarter, Halozyme Therapeutics (NASDAQ:HALO) received 2 bullish, 1 somewhat bullish, and 1 indifferent rating from analysts. The company's average 12-month price target is $56.75, which has increased by 3.8% over the past month.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 12:00 pm